News Summaries

Why One‑Time CAR‑T Shots Are Becoming the Go‑To for Tough Multiple Myeloma Cases

New research shows that CAR‑T cell therapy, especially the BCMA‑targeted drug ciltacabtagene autoleucel (cilta‑cel), is emerging as the preferred treatment for patients whose multiple myeloma has come back or stopped responding to other medicines. In a large Phase 3 trial (CARTITUDE‑4), a single infusion of cilta‑cel gave patients a 30‑month progression‑free survival rate of 59 % and an overall‑survival rate of 76 %, with more than 99 % responding to treatment and 72 % achieving deep, MRD‑negative remissions. These results were better than standard therapies and also improved quality of life. By contrast, the bispecific antibody combo teclistamab + daratumumab (tec‑dara) also works well but requires regular monthly injections, carries a higher infection risk, and its benefit in patients already exposed to CD38 antibodies (like daratumumab) is still uncertain. Real‑world data suggest CAR‑T remains effective even after CD38‑targeted drugs, while tec‑dara’s performance in that setting is less clear. Experts now recommend using CAR‑T first when both options are available, reserving bispecific antibodies for later lines of therapy. The single‑dose approach reduces treatment‑related “time toxicity,” avoids the need for ongoing IVIG support, and may offer a path toward long‑term remission or even cure for many patients. Access and logistical hurdles remain, but for most eligible patients, CAR‑T is the default choice.

AstraZeneca Teams Up with Owkin to Supercharge Drug Discovery with AI ‘Scientists’

AstraZeneca is stepping into the next era of drug development by signing a three‑year licensing agreement with AI specialist Owkin. The partnership gives the pharmaceutical giant access to Owkin’s K Pro platform – an “AI Scientist” that can sift through mountains of scientific papers, clinical trial data, and competitive intelligence in a fraction of the time it would take human researchers. Under the deal, Owkin will create custom AI agents tailored to AstraZeneca’s needs. One such agent will automatically track clinical‑trial activity for specific drug targets, monitor patient recruitment trends, predict possible outcomes, and even flag relevant patent filings. This automation aims to free up scientists to focus on creative problem‑solving while the AI handles the heavy lifting of data crunching. “We believe the future of the pharmaceutical industry is agentic,” said Thomas Clozel, Owkin’s co‑founder and CEO, highlighting the shift toward autonomous AI tools that can act independently within research pipelines. By harnessing these capabilities, AstraZeneca hopes to accelerate the pace of discovery, cut costs, and stay ahead in a fiercely competitive market. The collaboration marks another major step for big pharma as it embraces cutting‑edge artificial intelligence to bring new medicines to patients faster.

Scientists Build ‘Smart’ Cellular Trash System to Boost Cancer Immunotherapy

Researchers at Nanchang University have engineered a tiny “smart garbage disposal” that can sweep away disease‑causing proteins inside cells and make cancer‑fighting CAR‑T cells work better. The new tool, called pLIRTAC, is a short peptide that latches onto a cell’s natural recycling system (autophagy) and drags specific target proteins straight to the lysosome – the cell’s waste bin. In lab tests, pLIRTAC efficiently destroyed the AKT1 protein, a driver of aggressive brain tumors, slowing tumor growth. Even more exciting, the team fused pLIRTAC to the CAR‑T cell receptor, allowing the engineered T cells to self‑clean the proteins that normally cause them to tire out during therapy. This dual‑action design cut down the number of genetic tweaks needed to make CAR‑T cells and dramatically improved their persistence and tumor‑killing power in mice. Unlike older “PROTAC” drugs that rely on the proteasome and have many limitations, pLIRTAC uses the lysosomal route, which can handle a wider range of proteins, including those outside the cell. The study shows how harnessing the cell’s own waste‑disposal machinery could open new, less toxic ways to treat cancers and possibly other protein‑misfolding diseases.

Model Medicines Aims to Paint New ‘Colors’ in AI‑Powered Drug Discovery

When venture‑capitalist Daniel Haders, Ph.D., set out to find an AI‑driven drug‑discovery startup worth backing, he kept hitting a wall. The companies he met were using narrow, repetitive data sets that limited their ability to explore truly novel chemistry. “We realized the existing approaches were all looking at the same tiny slice of the chemical universe,” Haders told Fierce Biotech at their Boston conference. Determined to change the game, he gathered a team of scientists, engineers, and data experts to launch Model Medicines – a company built around the idea that AI needs a broader, more colorful palette to discover breakthrough medicines. The core challenge, Haders explained, is that AI models only learn from the data they’re fed. If the training data comes from a single, limited “blob” of chemical space, the algorithm will keep suggesting variations of the same old molecules, never venturing into unexplored regions where the next life‑saving drug might hide. Model Medicines is therefore focused on expanding its data library, incorporating diverse molecular structures, biological pathways, and real‑world patient information. By doing so, the company hopes its AI can spot hidden patterns, generate fresh drug candidates, and ultimately bring new treatments to patients faster and more efficiently than traditional methods. The goal? To discover new “colors” in the chemistry spectrum that could lead to the next generation of cancer therapies and beyond.

China’s Medical Device Market Set for Major Shake‑Up: How Centralized Procurement Is Driving Consolidation

China’s medical‑device sector has long been a jungle of 35,000 small firms, each earning only a few million yuan. By contrast, the country’s auto industry is dominated by ten giants that capture 84 % of sales, and the U.S. market is run by a handful of companies that generate hundreds of billions. This fragmentation limits R&D, drives price wars and hampers global competitiveness. A vivid illustration is the stapler market: 222 manufacturers vie for a 9.8 billion‑yuan pie, yet eight brands own 75 % of sales while the rest split the remaining quarter. High capital barriers mean tiny players cannot spread costs, leading to inevitable exits. Enter centralized procurement. Government‑led buying rounds have slashed stapler prices by 80‑98 %, lifted domestic‑brand market share above 80 % for open staplers, and forced many foreign‑origin firms out. The policy accelerates the industry’s natural lifecycle—from chaotic growth to a mature, concentrated structure where only firms with strong brands, innovation pipelines and cost efficiencies survive. Future procurement rounds will refine product grouping (class II/III, electric/manual) and emphasize clinical value over “lowest price.” This will reward innovators, prune homogeneous SMEs and push China’s medical‑device field toward a high‑end, globally competitive future.